Preloader

FOCUS 77L is an NGS-based liquid biopsy assay designed for patients with insufficient tissue for molecular testing, when repeat tissue biopsy is not feasible, and/or in cases of disease progression or suspected acquired resistance. By analyzing ctDNA in blood, it enables longitudinal monitoring of the tumor’s molecular profile.

The assay demonstrates high concordance with tissue-based genomic profiling and, in accordance with international guidelines (ASCO and ESMO), enables the sensitive detection of resistance-associated alterations that may emerge during treatment.

Applications:

  • When tissue samples are insufficient or repeat biopsy is not feasible,
  • In cases of disease progression or suspected acquired treatment resistance,
  • For the identification of resistance mutations,
  • For monitoring the tumor’s molecular profile during treatment,
  • For evaluating targeted therapy options.

Cancer Type: All solid tumors*
* For patients with non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) who have progressive disease and insufficient tissue for molecular analysis, liquid biopsy (cfDNA) is recognized by NCCN Guidelines as a critical diagnostic approach.

Technical Specifications

Method: NGS – Hybrid Capture

Coverage: ~10,000x (High Sensitivity)

Coverage: 77 Genes (Included in NCCN guidelines)

ALK, NTRK1, FGFR2, FGFR3, RET, and ROS1 (Fusions); EGFR, ERBB2, and MET (CNVs) genes 

Genetic Alterations Analyzed:

Detects SNV, Indel, Fusion, and CNV variants with a limit of detection (LoD) down to 0.1%.

Assay Kit:  ROCHE AVENIO ctDNA kit 

Sequencing System: Illumina NextSeq 550 DX (CE-IVD approved)

Bioinformatics System: Avenio

Accreditation: GENQA External Quality Assessment (EQA) & CAP Accreditation

Other Features:

The test features a Positive Predictive Value (PPV) of >99%, significantly minimizing false-positive rates.

Sample Requirements: 2 Streck Tubes

Turnaround Time (TAT): 10–14 days

* Please contact our laboratory for detailed sample submission requirements.
FOCUS 77 Liquid is performed in accordance with the requirements of the EMQN External Quality Assessment (EQA) program.

CAP accredited stampRoche logo

FoundationOne Medicine

//
Our customer support team is here to answer your questions!